Irinotecan

Generic Name: Irinotecan

Brand Names: Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₈N_₄O_₆

CAS Number: 97682-44-5

Unique Ingredient Identifier: 7673326042

Background: Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication: For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions: Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2005-08-31

Last Posted Date: 2008-04-01

Lead Sponsor: Pfizer

Target Recruit Count: 138

Registration Number: NCT00139711

Locations: 🇮🇹
Pfizer Investigational Site, Varses, Italy

Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants

Phase 4

Completed

Conditions: Metastatic Colorectal Cancer

First Posted Date: 2005-08-30

Last Posted Date: 2010-07-20

Lead Sponsor: Institut de Recherche Clinique sur les Cancers et le Sang

Target Recruit Count: 71

Registration Number: NCT00138060

Locations: 🇫🇷
Department of Oncology - CHLS, Pierre Benite, France
🇫🇷
Department of Gastroenterology, CHLS, Pierre Benite, France
🇫🇷
Department of Oncology, CHU, Grenoble, France

and more 3 locations

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Drug: irinotecan hydrochloride
Drug: temozolomide
Drug: vincristine sulfate

First Posted Date: 2005-08-30

Last Posted Date: 2023-10-02

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 42

Registration Number: NCT00138216

Locations: 🇺🇸
Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States
🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇨🇦
Hopital Sainte Justine, Montreal, Quebec, Canada

and more 15 locations

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Cisplatin
Drug: Irinotecan
Drug: Celecoxib
Procedure: Radiation Therapy
Procedure: Esophagectomy

First Posted Date: 2005-08-30

Last Posted Date: 2017-09-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT00137852

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Irinotecan Study For Cervical Cancer

Phase 2

Completed

Conditions: Uterine Cervical Neoplasms

Interventions: Drug: Irinotecan

First Posted Date: 2005-08-29

Last Posted Date: 2015-06-19

Lead Sponsor: Pfizer

Target Recruit Count: 41

Registration Number: NCT00136955

Locations: 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan

S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer

Phase 2

Conditions: Gastric Cancer

First Posted Date: 2005-08-24

Last Posted Date: 2013-09-17

Lead Sponsor: Fukushima Medical University Hospital

Target Recruit Count: 70

Registration Number: NCT00134095

Locations: 🇯🇵
Kobe City General Hospital, Kobe, Hyogo, Japan
🇯🇵
Yamamoto Kumiai General Hospital, Noshiro, Akita, Japan
🇯🇵
Tsuruoka Municipal Shonai Hospital, Tsuruoka, Yamagata, Japan

and more 4 locations

Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Stage III Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage III Colon Cancer

Interventions: Drug: sorafenib tosylate
Drug: cetuximab
Drug: irinotecan hydrochloride

First Posted Date: 2005-08-24

Last Posted Date: 2014-04-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00134069

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of Colorado at Denver Health Sciences Center, Aurora, Colorado, United States